Nanoform Finland Plc (“Nanoform”), a medicine performance-enhancing company, announced today that it will enter into a pre-clinical development agreement with Takeda Pharmaceuticals, Inc.’s Plasma-derived Therapies Business Unit to develop innovative plasma-derived therapy formulations for rare conditions.
After a unique plasma-derived therapeutic formulation’s in vitro proof of concept investigations are finished, Nanoform will give Takeda non-GMP nanomaterial for in vivo studies. Early in 2025, these studies should yield their first findings.
“Direct nanoforming of biologics is a promising new approach to allow more life-changing large-molecule medicines to reach the market,” commented Dr. Edward Haeggström, CEO of Nanoform. “We look forward to entering in vivo studies together with Takeda and expanding our already very positive relationship.”
This pre-clinical (non-GMP) project’s value is consistent with the €0.05 million to €0.5 million guided business model of Nanoform for non-GMP projects. Both Takeda and Nanoform want to create potential medicines, get them into clinical trials, and finally bring the finished goods to market.
Read also- Hong Kong-Based Cyberport Collaborate with HKMA
Using nanoforming technology, Nanoform Biologics can deliver biologically active large-molecule medication particles with tunable size and morphology.
Read also- Singapore-Based MAS Collaborate with Banks
From 1 to 150 KDa, the technology can be used in the biologics area to enable new medication combinations, improve drug loading, and develop innovative routes of delivery.
About Takeda
Takeda is a patient-focused, values-based, R&D-driven global biopharmaceutical business dedicated to Better Health and a Brighter Future. Over 230 years of Japanese history inspires the search of potentially life-changing patient therapies.
About Nanoform
Nanoform enhances patient medicine performance with best-in-class nanoparticle engineering technology, skilled formulation, and scalable GMP API manufacturing. The company uses nanoforming technology and formulation services from pre-formulation to commercial scale to reduce clinical attrition and improve drug molecule performance.
